Ron Taylor - Allergan Plc Independent Director
Director
Mr. Ronald R. Taylor is an Independent Director of Allergan Plc. Mr. Taylor joined the Board of Directors in 1994 since 2013.
| Age | 67 |
| Tenure | 11 years |
| Phone | 862 261 7000 |
| Web | http://www.allergan.com |
Allergan Plc Management Efficiency
The company has Return on Asset of (0.0564) % which means that on every $100 spent on assets, it lost $0.0564. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (0.0913) %, meaning that it generated no profit with money invested by stockholders. Allergan Plc's management efficiency ratios could be used to measure how well Allergan Plc manages its routine affairs as well as how well it operates its assets and liabilities.The company has 23.08 B in debt with debt to equity (D/E) ratio of 39.4, demonstrating that the company may be unable to create cash to meet all of its financial commitments. Allergan Plc has a current ratio of 0.98, suggesting that it has not enough short term capital to pay financial commitments when the payables are due. Debt can assist Allergan Plc until it has trouble settling it off, either with new capital or with free cash flow. So, Allergan Plc's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Allergan Plc sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Allergan to invest in growth at high rates of return. When we think about Allergan Plc's use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Michael Dominguez | CDW Corp | 45 | |
| Michael Maples | Q2 Holdings | 75 | |
| Siew Choy | FactSet Research Systems | 54 | |
| Michael Brown | Q2 Holdings | 44 | |
| Virginia Addicott | CDW Corp | 54 | |
| Benjamin Chereskin | CDW Corp | 59 | |
| Joseph Swedish | CDW Corp | 66 | |
| Malcolm Frank | FactSet Research Systems | 54 | |
| James Bell | CDW Corp | 69 | |
| Barry Allen | CDW Corp | 69 | |
| Lynn Atchison | Q2 Holdings | 58 | |
| Joseph Zimmel | FactSet Research Systems | 67 | |
| Paul Finnegan | CDW Corp | 65 | |
| Carl Schaper | Q2 Holdings | 66 | |
| Lynn Tyson | Q2 Holdings | N/A | |
| David Nelms | CDW Corp | 57 | |
| Lynda Clarizio | CDW Corp | 57 | |
| Glenn Creamer | CDW Corp | 53 | |
| Steven Alesio | CDW Corp | 64 | |
| Jeffrey Diehl | Q2 Holdings | 50 | |
| Joseph Laird | FactSet Research Systems | 69 | |
Management Performance
| Return On Equity | -0.0913 | |||
| Return On Asset | -0.0564 |
Allergan Plc Leadership Team
Elected by the shareholders, the Allergan Plc's board of directors comprises two types of representatives: Allergan Plc inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Allergan. The board's role is to monitor Allergan Plc's management team and ensure that shareholders' interests are well served. Allergan Plc's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Allergan Plc's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Matthew Walsh, Chief Financial Officer, Executive Vice President | ||
| Robert Bailey, Chief Legal Officer and Corporate Secretary | ||
| Robert Stewart, Executive VP and President of Generic and Global Operations | ||
| Ronald Taylor, Independent Director | ||
| Adriane Brown, Independent Director | ||
| William Meury, Executive Vice President, Chief Commercial Officer | ||
| Brenton Saunders, Chairman of the Board, President, Chief Executive Officer | ||
| Wayne Swanton, Executive Vice President - Global Operations | ||
| Robert Hugin, Independent Director | ||
| Nicholson, Chief R&D Officer | ||
| Christopher Bodine, Independent Director | ||
| Karen Ling, Chief Human Resource Officer, Executive Vice President | ||
| Michael Gallagher, Lead Independent Director | ||
| Paul Bisaro, Executive Chairman | ||
| Thomas Freyman, Independent Director | ||
| Catherine Klema, Lead Independent Director | ||
| James DArecca, Chief Accounting Officer | ||
| Christopher Coughlin, Lead Independent Director | ||
| Nesli Basgoz, Independent Director | ||
| Philippe Schaison, Executive Vice President and President Allergan Medical | ||
| Maria Hilado, CFO and Executive VP | ||
| Joseph Boccuzi, Independent Director | ||
| Patrick OSullivan, Independent Director | ||
| Fred Weiss, Independent Director | ||
| A Bailey, Executive Vice President, Chief Legal Officer and Corporate Secretary | ||
| Alex Kelly, Chief Communications Officer | ||
| CDavid Nicholson, Executive Vice President, Chief R&D Officer | ||
| Carol Davidson, Independent Director | ||
| Michael Greenberg, Independent Director | ||
| Ron Taylor, Independent Director | ||
| Jonathon Kellerman, Executive Vice President Chief Compliance Officer | ||
| Paul Navarre, Executive Vice President and President International Brands | ||
| James Bloem, Independent Director | ||
| Karina Calzadilla, IR Contact Officer | ||
| Peter McDonnell, Independent Director |
Allergan Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Allergan Plc a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.0913 | |||
| Return On Asset | -0.0564 | |||
| Profit Margin | (0) % | |||
| Operating Margin | 6.84 % | |||
| Current Valuation | 81.41 B | |||
| Shares Outstanding | 328.1 M | |||
| Shares Owned By Insiders | 0.16 % | |||
| Shares Owned By Institutions | 98.25 % | |||
| Number Of Shares Shorted | 15.01 M | |||
| Price To Earning | 24.00 X |
Pair Trading with Allergan Plc
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Allergan Plc position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Allergan Plc will appreciate offsetting losses from the drop in the long position's value.The ability to find closely correlated positions to Expedia could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Expedia when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Expedia - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Expedia Group to buy it.
The correlation of Expedia is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Expedia moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Expedia Group moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Expedia can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in price. Note that the Allergan Plc information on this page should be used as a complementary analysis to other Allergan Plc's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Sign In To Macroaxis module to sign in to explore Macroaxis' wealth optimization platform and fintech modules.
Other Consideration for investing in Allergan Stock
If you are still planning to invest in Allergan Plc check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Allergan Plc's history and understand the potential risks before investing.
| CEOs Directory Screen CEOs from public companies around the world | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities |